Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Ведение женщин в менопаузе с эндометриозом в анамнезе
Ведение женщин в менопаузе с эндометриозом в анамнезе
Ермакова Е.И., Юренева С.В. Ведение женщин в менопаузе с эндометриозом в анамнезе. Гинекология. 2019; 21 (6): 41–44.
DOI: 10.26442/20795696.2019.6.190662
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Цель. Сформулировать позицию по ведению женщин в менопаузе с эндометриозом с точки зрения доказательной медицины.
Материалы и методы. Отечественные и зарубежные клинические рекомендации, позиция Международного общества по менопаузе (IMS), Европейского общества по менопаузе и андропаузе (EMAS).
Результаты. В статье приведены основные режимы и пути введения менопаузальной гормональной терапии и их преимущества. Освещена экспертная позиция по поводу ведения пациенток с эндометриозом в анамнезе в период хирургической и естественной менопаузы. Приведены сведения о распространенности и методах лечения постменопаузального эндометриоза.
Ключевые слова: менопауза, хирургическая менопауза, эстрогенный дефицит, климактерические расстройства, эндометриоз, постменопаузальный эндометриоз, менопаузальная гормональная терапия.
Materials and methods. Review of domestic and foreign literature, position of IMS and EMAS.
Results. The article describes the main modes snd ways of introducing MHT and their advantages. The expert position on the management of patients with a history of endometriosis during surgical and natural menopause is highlighted. Information on the prevalence and methods of treatment of postmenopausal endometriosis is given.
Key words: menopause, surgical menopause, estrogen deficiency, menopausal disorders, endometriosis, postmenopausal endometriosis, menopausal hormone therapy.
Материалы и методы. Отечественные и зарубежные клинические рекомендации, позиция Международного общества по менопаузе (IMS), Европейского общества по менопаузе и андропаузе (EMAS).
Результаты. В статье приведены основные режимы и пути введения менопаузальной гормональной терапии и их преимущества. Освещена экспертная позиция по поводу ведения пациенток с эндометриозом в анамнезе в период хирургической и естественной менопаузы. Приведены сведения о распространенности и методах лечения постменопаузального эндометриоза.
Ключевые слова: менопауза, хирургическая менопауза, эстрогенный дефицит, климактерические расстройства, эндометриоз, постменопаузальный эндометриоз, менопаузальная гормональная терапия.
________________________________________________
Materials and methods. Review of domestic and foreign literature, position of IMS and EMAS.
Results. The article describes the main modes snd ways of introducing MHT and their advantages. The expert position on the management of patients with a history of endometriosis during surgical and natural menopause is highlighted. Information on the prevalence and methods of treatment of postmenopausal endometriosis is given.
Key words: menopause, surgical menopause, estrogen deficiency, menopausal disorders, endometriosis, postmenopausal endometriosis, menopausal hormone therapy.
Полный текст
Список литературы
1. Юренева С.В., Ермакова Е.И. Ведение женщин с менопаузальными расстройствами (обзор клинических рекомендаций). Проблемы репродукции. 2017; 5: 25–9.
[Iureneva S.V., Ermakova E.I. Vedenie zhenshchin s menopauzal'nymi rasstroistvami (obzor klinicheskikh rekomendatsii). Problemy reproduktsii. 2017; 5: 25–9 (in Russian).]
2. Baber RJ, Panay N, Fenton A, and the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19 (2): 109–50.
3. The 2017 hormone therapy position statement of The North American Menopause Society NAMS. Menopause. J North Am Menopause Soc 2017; 24 (7).
4. Stuenkel CA, Davis SR, Gompel A. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015: 100 (11): 3975–4011.
5. Black A, Guilber E, Costescu D. Sogc clinical practice guideline. Canadian Contraception Consensus (Part 3 of 4): Chapter 7 – Intrauterine Contraception. No. 329. J Obstet Gynaecol Can 2016; 38 (2): 182–222.
6. Юренева С.В., Ермакова Е.И. Менопауза и климактерическое состояние у женщины. Акушерство и гинекология. 2018; 7: 32–9.
[Iureneva S.V., Ermakova E.I. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Akusherstvo i ginekologiia. 2018; 7: 32–9 (in Russian).]
7. Streuli I, Gaitzsch H, Wenger JM, Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition. Climacteric 2017; 20 (2): 138–43.
8. Eid S, Loukas M, Tubbs RS. Clinical anatomy of pelvic pain in women: A Gynecological Perspective. Clin Anat 2019; 32 (1): 151–5. DOI: 10.1002/ca.23270
9. Tan DA, Almaria MJG. Postmenopausal endometriosis: drawing a clearer clinical picture. Climacteric 2018; 21 (3): 249–55. DOI: 10.1080/13697137.2018.1450855
10. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev 2009; 1.
11. Shuster LT, Rhodes DJ, Gostout BS et al. Premature menopause or early menopause: long-term health consequences. Maturitas 2010; 65: 161–6.
12. Umit Inceboz Endometriosis after menopause. Womens Health 2015; 11 (5): 711–5.
13. Moen MH, Rees M, Brincat M et al. EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas 2010; 67: 94–7.
14. Nikkanen V, Punnonen R. External endometriosis in 801 operated patients. Acta Obstet Gynecol Scand 1984; 63 (8): 699–701.
15. Haas D, Chvatal R, Reichert B. Endometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis. Arch Gynecol Obstet 2012; 286 (3): 667–70.
16. Matorras R, Elorriaga MA, Pioan JI et al. Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy. Fertil Steril 2002; 77 (2): 303–8.
17. Rattanachaiyanont M, Tanmahasamut P, Angsuwatthana S et al. Hormonal replacement therapy in surgical menopause with underlying endometriosis. J Med Assoc Thai 2005; 86 (8): 702–7.
18. Hickman TN, Namnoum AB, Hinton EL et al. Timing of ERT following hysterectomy with oophorectomy for endometriosis. Obstet Gynecol 2008; 91: 673–7.
19. Green-top guideline No. 24 RCOG. The investigation and managementof endometriosis. http://www.rcog.org.uk/files/rcog-corp/uploadedfiles/GT24InvestigationEndometriosis2006.pdf; January 2010.
20. ESHRE guideline for the diagnosis and treatment of endometriosis. http://guidelines.endometriosis.org; January 2010.
21. Bohrer J, Chen CC, Falcone T. Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. Fertil Steril 2008; 90 (5): 2–9.
22. Sasson IE, Taylor HS. Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman. Fertil Steril 2009; 92 (3): 1170.
23. Słopień R, Męczekalski B. Aromatase inhibitors in the treatment of endometriosis. Prz Menopauzalny 2016; 15 (1): 43–7. DOI: 10.5114/pm.2016.58773
24. Abu Hashim H. Potential role of aromatase inhibitors in the treatment of endometriosis. Int J Womens Health 2014; 6: 671–80. DOI: 10.2147/IJWH.S34684
25. Thomsen LH, Schnack TH, Buchardi K. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand 2017; 96: 761–78.
26. Herreros-Villanueva M, Chen CC, Tsai EM, Er TK. Endometriosis-associated ovarian cancer: What have we learned so far? Clin Chim Acta 2019; 493: 63–72. DOI: 10.1016/j.cca.2019.02.016
27. Barreta A, Sarian L, Ferracini AC et al. Endometriosis-Associated Ovarian Cancer: Population Characteristics and Prognosis. Int J Gynecol Cancer 2018; 28 (7): 1251–7. DOI: 10.1097/IGC.0000000000001317
28. Ghafoor S, Lakhman Y, Park KJ, Petkovska I. Polypoid endometriosis: a mimic of malignancy. Abdom Radiol (NY) 2019. DOI: 10.1007/s00261-019-02143-8
29. Yoshino O, Minamisaka T, Ono Y et al.Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments.
J Obstet Gynaecol Res 2018; 44 (9): 1850–8. DOI: 10.1111/jog.13702
30. Gandini S, Lazzeroni M, Peccatori FA et al. The risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysis. Crit Rev Oncol Hematol 2019; 134: 72–81. DOI: 10.1016/j.critrevonc.2018.12.009
2. Baber RJ, Panay N, Fenton A, and the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19 (2): 109–50.
3. The 2017 hormone therapy position statement of The North American Menopause Society NAMS. Menopause. J North Am Menopause Soc 2017; 24 (7).
4. Stuenkel CA, Davis SR, Gompel A. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015: 100 (11): 3975–4011.
5. Black A, Guilber E, Costescu D. Sogc clinical practice guideline. Canadian Contraception Consensus (Part 3 of 4): Chapter 7 – Intrauterine Contraception. No. 329. J Obstet Gynaecol Can 2016; 38 (2): 182–222.
6. Iureneva S.V., Ermakova E.I. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Akusherstvo i ginekologiia. 2018; 7: 32–9 (in Russian).
7. Streuli I, Gaitzsch H, Wenger JM, Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition. Climacteric 2017; 20 (2): 138–43.
8. Eid S, Loukas M, Tubbs RS. Clinical anatomy of pelvic pain in women: A Gynecological Perspective. Clin Anat 2019; 32 (1): 151–5. DOI: 10.1002/ca.23270
9. Tan DA, Almaria MJG. Postmenopausal endometriosis: drawing a clearer clinical picture. Climacteric 2018; 21 (3): 249–55. DOI: 10.1080/13697137.2018.1450855
10. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev 2009; 1.
11. Shuster LT, Rhodes DJ, Gostout BS et al. Premature menopause or early menopause: long-term health consequences. Maturitas 2010; 65: 161–6.
12. Umit Inceboz Endometriosis after menopause. Womens Health 2015; 11 (5): 711–5.
13. Moen MH, Rees M, Brincat M et al. EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas 2010; 67: 94–7.
14. Nikkanen V, Punnonen R. External endometriosis in 801 operated patients. Acta Obstet Gynecol Scand 1984; 63 (8): 699–701.
15. Haas D, Chvatal R, Reichert B. Endometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis. Arch Gynecol Obstet 2012; 286 (3): 667–70.
16. Matorras R, Elorriaga MA, Pioan JI et al. Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy. Fertil Steril 2002; 77 (2): 303–8.
17. Rattanachaiyanont M, Tanmahasamut P, Angsuwatthana S et al. Hormonal replacement therapy in surgical menopause with underlying endometriosis. J Med Assoc Thai 2005; 86 (8): 702–7.
18. Hickman TN, Namnoum AB, Hinton EL et al. Timing of ERT following hysterectomy with oophorectomy for endometriosis. Obstet Gynecol 2008; 91: 673–7.
19. Green-top guideline No. 24 RCOG. The investigation and managementof endometriosis. http://www.rcog.org.uk/files/rcog-corp/uploadedfiles/GT24InvestigationEndometriosis2006.pdf; January 2010.
20. ESHRE guideline for the diagnosis and treatment of endometriosis. http://guidelines.endometriosis.org; January 2010.
21. Bohrer J, Chen CC, Falcone T. Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. Fertil Steril 2008; 90 (5): 2–9.
22. Sasson IE, Taylor HS. Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman. Fertil Steril 2009; 92 (3): 1170.
23. Słopień R, Męczekalski B. Aromatase inhibitors in the treatment of endometriosis. Prz Menopauzalny 2016; 15 (1): 43–7. DOI: 10.5114/pm.2016.58773
24. Abu Hashim H. Potential role of aromatase inhibitors in the treatment of endometriosis. Int J Womens Health 2014; 6: 671–80. DOI: 10.2147/IJWH.S34684
25. Thomsen LH, Schnack TH, Buchardi K. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand 2017; 96: 761–78.
26. Herreros-Villanueva M, Chen CC, Tsai EM, Er TK. Endometriosis-associated ovarian cancer: What have we learned so far? Clin Chim Acta 2019; 493: 63–72. DOI: 10.1016/j.cca.2019.02.016
27. Barreta A, Sarian L, Ferracini AC et al. Endometriosis-Associated Ovarian Cancer: Population Characteristics and Prognosis. Int J Gynecol Cancer 2018; 28 (7): 1251–7. DOI: 10.1097/IGC.0000000000001317
28. Ghafoor S, Lakhman Y, Park KJ, Petkovska I. Polypoid endometriosis: a mimic of malignancy. Abdom Radiol (NY) 2019. DOI: 10.1007/s00261-019-02143-8
29. Yoshino O, Minamisaka T, Ono Y et al.Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments.
J Obstet Gynaecol Res 2018; 44 (9): 1850–8. DOI: 10.1111/jog.13702
30. Gandini S, Lazzeroni M, Peccatori FA et al. The risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysis. Crit Rev Oncol Hematol 2019; 134: 72–81. DOI: 10.1016/j.critrevonc.2018.12.009
[Iureneva S.V., Ermakova E.I. Vedenie zhenshchin s menopauzal'nymi rasstroistvami (obzor klinicheskikh rekomendatsii). Problemy reproduktsii. 2017; 5: 25–9 (in Russian).]
2. Baber RJ, Panay N, Fenton A, and the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19 (2): 109–50.
3. The 2017 hormone therapy position statement of The North American Menopause Society NAMS. Menopause. J North Am Menopause Soc 2017; 24 (7).
4. Stuenkel CA, Davis SR, Gompel A. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015: 100 (11): 3975–4011.
5. Black A, Guilber E, Costescu D. Sogc clinical practice guideline. Canadian Contraception Consensus (Part 3 of 4): Chapter 7 – Intrauterine Contraception. No. 329. J Obstet Gynaecol Can 2016; 38 (2): 182–222.
6. Юренева С.В., Ермакова Е.И. Менопауза и климактерическое состояние у женщины. Акушерство и гинекология. 2018; 7: 32–9.
[Iureneva S.V., Ermakova E.I. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Akusherstvo i ginekologiia. 2018; 7: 32–9 (in Russian).]
7. Streuli I, Gaitzsch H, Wenger JM, Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition. Climacteric 2017; 20 (2): 138–43.
8. Eid S, Loukas M, Tubbs RS. Clinical anatomy of pelvic pain in women: A Gynecological Perspective. Clin Anat 2019; 32 (1): 151–5. DOI: 10.1002/ca.23270
9. Tan DA, Almaria MJG. Postmenopausal endometriosis: drawing a clearer clinical picture. Climacteric 2018; 21 (3): 249–55. DOI: 10.1080/13697137.2018.1450855
10. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev 2009; 1.
11. Shuster LT, Rhodes DJ, Gostout BS et al. Premature menopause or early menopause: long-term health consequences. Maturitas 2010; 65: 161–6.
12. Umit Inceboz Endometriosis after menopause. Womens Health 2015; 11 (5): 711–5.
13. Moen MH, Rees M, Brincat M et al. EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas 2010; 67: 94–7.
14. Nikkanen V, Punnonen R. External endometriosis in 801 operated patients. Acta Obstet Gynecol Scand 1984; 63 (8): 699–701.
15. Haas D, Chvatal R, Reichert B. Endometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis. Arch Gynecol Obstet 2012; 286 (3): 667–70.
16. Matorras R, Elorriaga MA, Pioan JI et al. Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy. Fertil Steril 2002; 77 (2): 303–8.
17. Rattanachaiyanont M, Tanmahasamut P, Angsuwatthana S et al. Hormonal replacement therapy in surgical menopause with underlying endometriosis. J Med Assoc Thai 2005; 86 (8): 702–7.
18. Hickman TN, Namnoum AB, Hinton EL et al. Timing of ERT following hysterectomy with oophorectomy for endometriosis. Obstet Gynecol 2008; 91: 673–7.
19. Green-top guideline No. 24 RCOG. The investigation and managementof endometriosis. http://www.rcog.org.uk/files/rcog-corp/uploadedfiles/GT24InvestigationEndometriosis2006.pdf; January 2010.
20. ESHRE guideline for the diagnosis and treatment of endometriosis. http://guidelines.endometriosis.org; January 2010.
21. Bohrer J, Chen CC, Falcone T. Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. Fertil Steril 2008; 90 (5): 2–9.
22. Sasson IE, Taylor HS. Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman. Fertil Steril 2009; 92 (3): 1170.
23. Słopień R, Męczekalski B. Aromatase inhibitors in the treatment of endometriosis. Prz Menopauzalny 2016; 15 (1): 43–7. DOI: 10.5114/pm.2016.58773
24. Abu Hashim H. Potential role of aromatase inhibitors in the treatment of endometriosis. Int J Womens Health 2014; 6: 671–80. DOI: 10.2147/IJWH.S34684
25. Thomsen LH, Schnack TH, Buchardi K. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand 2017; 96: 761–78.
26. Herreros-Villanueva M, Chen CC, Tsai EM, Er TK. Endometriosis-associated ovarian cancer: What have we learned so far? Clin Chim Acta 2019; 493: 63–72. DOI: 10.1016/j.cca.2019.02.016
27. Barreta A, Sarian L, Ferracini AC et al. Endometriosis-Associated Ovarian Cancer: Population Characteristics and Prognosis. Int J Gynecol Cancer 2018; 28 (7): 1251–7. DOI: 10.1097/IGC.0000000000001317
28. Ghafoor S, Lakhman Y, Park KJ, Petkovska I. Polypoid endometriosis: a mimic of malignancy. Abdom Radiol (NY) 2019. DOI: 10.1007/s00261-019-02143-8
29. Yoshino O, Minamisaka T, Ono Y et al.Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments.
J Obstet Gynaecol Res 2018; 44 (9): 1850–8. DOI: 10.1111/jog.13702
30. Gandini S, Lazzeroni M, Peccatori FA et al. The risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysis. Crit Rev Oncol Hematol 2019; 134: 72–81. DOI: 10.1016/j.critrevonc.2018.12.009
________________________________________________
2. Baber RJ, Panay N, Fenton A, and the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19 (2): 109–50.
3. The 2017 hormone therapy position statement of The North American Menopause Society NAMS. Menopause. J North Am Menopause Soc 2017; 24 (7).
4. Stuenkel CA, Davis SR, Gompel A. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015: 100 (11): 3975–4011.
5. Black A, Guilber E, Costescu D. Sogc clinical practice guideline. Canadian Contraception Consensus (Part 3 of 4): Chapter 7 – Intrauterine Contraception. No. 329. J Obstet Gynaecol Can 2016; 38 (2): 182–222.
6. Iureneva S.V., Ermakova E.I. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Akusherstvo i ginekologiia. 2018; 7: 32–9 (in Russian).
7. Streuli I, Gaitzsch H, Wenger JM, Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition. Climacteric 2017; 20 (2): 138–43.
8. Eid S, Loukas M, Tubbs RS. Clinical anatomy of pelvic pain in women: A Gynecological Perspective. Clin Anat 2019; 32 (1): 151–5. DOI: 10.1002/ca.23270
9. Tan DA, Almaria MJG. Postmenopausal endometriosis: drawing a clearer clinical picture. Climacteric 2018; 21 (3): 249–55. DOI: 10.1080/13697137.2018.1450855
10. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev 2009; 1.
11. Shuster LT, Rhodes DJ, Gostout BS et al. Premature menopause or early menopause: long-term health consequences. Maturitas 2010; 65: 161–6.
12. Umit Inceboz Endometriosis after menopause. Womens Health 2015; 11 (5): 711–5.
13. Moen MH, Rees M, Brincat M et al. EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas 2010; 67: 94–7.
14. Nikkanen V, Punnonen R. External endometriosis in 801 operated patients. Acta Obstet Gynecol Scand 1984; 63 (8): 699–701.
15. Haas D, Chvatal R, Reichert B. Endometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis. Arch Gynecol Obstet 2012; 286 (3): 667–70.
16. Matorras R, Elorriaga MA, Pioan JI et al. Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy. Fertil Steril 2002; 77 (2): 303–8.
17. Rattanachaiyanont M, Tanmahasamut P, Angsuwatthana S et al. Hormonal replacement therapy in surgical menopause with underlying endometriosis. J Med Assoc Thai 2005; 86 (8): 702–7.
18. Hickman TN, Namnoum AB, Hinton EL et al. Timing of ERT following hysterectomy with oophorectomy for endometriosis. Obstet Gynecol 2008; 91: 673–7.
19. Green-top guideline No. 24 RCOG. The investigation and managementof endometriosis. http://www.rcog.org.uk/files/rcog-corp/uploadedfiles/GT24InvestigationEndometriosis2006.pdf; January 2010.
20. ESHRE guideline for the diagnosis and treatment of endometriosis. http://guidelines.endometriosis.org; January 2010.
21. Bohrer J, Chen CC, Falcone T. Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. Fertil Steril 2008; 90 (5): 2–9.
22. Sasson IE, Taylor HS. Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman. Fertil Steril 2009; 92 (3): 1170.
23. Słopień R, Męczekalski B. Aromatase inhibitors in the treatment of endometriosis. Prz Menopauzalny 2016; 15 (1): 43–7. DOI: 10.5114/pm.2016.58773
24. Abu Hashim H. Potential role of aromatase inhibitors in the treatment of endometriosis. Int J Womens Health 2014; 6: 671–80. DOI: 10.2147/IJWH.S34684
25. Thomsen LH, Schnack TH, Buchardi K. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand 2017; 96: 761–78.
26. Herreros-Villanueva M, Chen CC, Tsai EM, Er TK. Endometriosis-associated ovarian cancer: What have we learned so far? Clin Chim Acta 2019; 493: 63–72. DOI: 10.1016/j.cca.2019.02.016
27. Barreta A, Sarian L, Ferracini AC et al. Endometriosis-Associated Ovarian Cancer: Population Characteristics and Prognosis. Int J Gynecol Cancer 2018; 28 (7): 1251–7. DOI: 10.1097/IGC.0000000000001317
28. Ghafoor S, Lakhman Y, Park KJ, Petkovska I. Polypoid endometriosis: a mimic of malignancy. Abdom Radiol (NY) 2019. DOI: 10.1007/s00261-019-02143-8
29. Yoshino O, Minamisaka T, Ono Y et al.Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments.
J Obstet Gynaecol Res 2018; 44 (9): 1850–8. DOI: 10.1111/jog.13702
30. Gandini S, Lazzeroni M, Peccatori FA et al. The risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysis. Crit Rev Oncol Hematol 2019; 134: 72–81. DOI: 10.1016/j.critrevonc.2018.12.009
Авторы
Е.И. Ермакова*, С.В. Юренева
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова» Минздрава России, Москва, Россия
*ermakova.health@mail.ru
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*ermakova.health@mail.ru
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова» Минздрава России, Москва, Россия
*ermakova.health@mail.ru
________________________________________________
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*ermakova.health@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.